Journal of Diabetes Research · 2019 · 29 citations · 40 references
MedicineEndocrinologyPharmacologyAutoimmunityImmunotherapyInflammationDiabetes MellitusDiabetes PharmacotherapyGabaergic PharmacologyGlycemic ControlMetabolic InflammationSodium-glucose Cotransporter 2 InhibitorsBeta-cell DysfunctionGamma-aminobutyric Acid ModulatorsImpaired Glucose ToleranceIslet Cell DysfunctionIslet Cell MassSodium-dependent Glucose TransportSodium-dependent Glucose TransportersType 1 Diabetes Pathophysiology
While the autoimmune character of T1D (type 1 diabetes) is being challenged, it is currently recognized that inflammation plays a key role in its development. We hypothesized that glucotoxicity could contribute to β -cell mass destruction through participation in islet inflammation. We evaluated the potential of empagliflozin (EMPA) and GABA (gamma-aminobutyric acid) to protect β -cell mass against glucotoxicity and to increase β -cell mass after diagnosis of T1D. Empagliflozin is a SGLT2 (sodium-dependent glucose cotransporter) inhibitor which thereby blocks glucose recapture by the kidney and promotes glucose excretion in urine. GABA is an inhibitory neurotransmitter, which stimulates α -to- β cell transdifferentiation. In streptozotocin-treated mice, empagliflozin and/or GABA were delivered for a period of five days or three weeks. As compared to untreated T1D mice, EMPA-treated T1D mice had decreased FFA (free fatty acid) levels and improved glucose homeostasis. EMPA-treated T1D mice had higher islet density, with preserved architecture, compared to T1D mice, and EMPA-treated T1D mice also differed from T1D mice by the total absence of immune cell infiltration within islets. Islets from EMPA-treated mice were also less subjected to ER (endoplasmic reticulum) stress and inflammation, as shown by qPCR analysis. Glucose homeostasis parameters and islet area/pancreas area ratio improved, as compared to diabetic controls, when T1D mice were treated for three weeks with GABA and EMPA. T1D EMPA+GABA mice had higher glucagon levels than T1D mice, without modifications of glucagon area/islet area ratios. In conclusion, empagliflozin and GABA, used in monotherapy in streptozotocin-induced diabetic mice, have positive effects on β -cell mass preservation or proliferation through an indirect effect on islet cell inflammation and ER stress. Further research is mandatory to evaluate whether empagliflozin and GABA may be a potential therapeutic target for the protection of β -cell mass after new-onset T1D.
40
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Alexandra E. Butler, Juliette Janson, Susan Bonner‐Weir et al. · Diabetes · 2003 · 4K citations
Medicine, Endocrinology, Physiology +17
In vivo reprogramming of adult pancreatic exocrine cells to β-cells
Qiao Zhou, Juliana Brown, Andrew Kanarek et al. · Nature · 2008 · 2K citations · Full text
Conversion of adult pancreatic α-cells to β-cells after extreme β-cell loss
Fabrizio Thorel, Virginie Népote, Isabelle Avril et al. · Nature · 2010 · 1.1K citations · Full text